Name (Synonyms) | Correlation | |
---|---|---|
drug2868 | leucovorin Wiki | 0.50 |
drug2672 | Voraxaze Wiki | 0.50 |
drug2104 | Rituximab Wiki | 0.50 |
drug566 | Chloroquine or Hydroxychloroquine Wiki | 0.29 |
drug1822 | Placebo Wiki | 0.03 |
There are 4 clinical trials
The purpose of this study is to test the effects of a drug called Voraxaze when it's routinely given in combination with methotrexate and rituximab, the standard treatment for CNSL.
Description: All serum samples will be tested via MTX immunoassay (measures MTX levels in addition to byproducts) as well as HPLC or mass spectroscopy which will reveal plasma concentrations of MTX and DAMPA separately.
Measure: number of patients that have significant reduction of serum methotrexate levels Time: 1 yearThe aim of this study is to evaluate the efficacy and safety of MTX-loaded nanoparticles in three different doses to treat severe COVID-19 patients.
Description: Clinical condition will be measured by lung injuries
Measure: Change in clinical conditions Time: 21 daysDescription: Evaluation of Pneumonia change
Measure: Change of Clinical symptoms - respiratory rate Time: 21 daysDescription: oxygen saturation
Measure: Hypoxia Time: 21 daysDescription: PaO2 / FiO2 ratio
Measure: Changes of blood oxygen Time: 21 daysDescription: C-reactive protein and ferritin
Measure: Inflammatory parameters Time: 21 daysDescription: Time to wean off oxygen invasive ventilatory support
Measure: Evolution of Acute Respiratory Syndrome Time: 21 daysDescription: Time to be discharged from hospital
Measure: Hospital discharge Time: 21 dyasDescription: Time to be discharged from ICU
Measure: ICU discharge Time: 21 daysDescription: Evaluation of change in acute respiratory syndrome
Measure: Rate of mortality Time: 4 monthsThe aim of this study is to evaluate the efficacy and safety of MTX-loaded nanoparticles in three different doses to treat severe COVID-19 patients.
Description: Clinical condition will be measured by lung injuries
Measure: Change in clinical conditions Time: 21 daysDescription: Evaluation of Pneumonia change
Measure: Change of Clinical symptoms - respiratory rate Time: 21 daysDescription: oxygen saturation
Measure: Hypoxia Time: 21 daysDescription: PaO2 / FiO2 ratio
Measure: Changes of blood oxygen Time: 21 daysDescription: C-reactive protein and ferritin
Measure: Inflammatory parameters Time: 21 daysDescription: Time to wean off oxygen invasive ventilatory support
Measure: Evolution of Acute Respiratory Syndrome Time: 21 daysDescription: Time to be discharged from hospital
Measure: Hospital discharge Time: 21 dyasDescription: Time to be discharged from ICU
Measure: ICU discharge Time: 21 daysDescription: Evaluation of change in acute respiratory syndrome
Measure: Rate of mortality Time: 4 monthsThe aim of this study is to evaluate the efficacy and safety of MTX-loaded nanoparticles in three different doses to treat severe COVID-19 patients.
Description: Clinical condition will be measured by lung injuries
Measure: Change in clinical conditions Time: 21 daysDescription: Evaluation of Pneumonia change
Measure: Change of Clinical symptoms - respiratory rate Time: 21 daysDescription: oxygen saturation
Measure: Hypoxia Time: 21 daysDescription: PaO2 / FiO2 ratio
Measure: Changes of blood oxygen Time: 21 daysDescription: C-reactive protein and ferritin
Measure: Inflammatory parameters Time: 21 daysDescription: Time to wean off oxygen invasive ventilatory support
Measure: Evolution of Acute Respiratory Syndrome Time: 21 daysDescription: Time to be discharged from hospital
Measure: Hospital discharge Time: 21 dyasDescription: Time to be discharged from ICU
Measure: ICU discharge Time: 21 daysDescription: Evaluation of change in acute respiratory syndrome
Measure: Rate of mortality Time: 4 months